nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2024 | editorial

Molecular tumor board—editorial

verfasst von: Priv. Doz. Dr. Hossein Taghizadeh, Prof. Dr. Armin Gerger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Auszug

Precision oncology is transforming the landscape of cancer treatment by leveraging molecular profiling techniques to tailor therapeutic strategies to the unique genetic makeup of each patient’s disease. Two recent articles delve into critical aspects of this evolving field: the role of molecular tumor boards (MTBs) and the integration of liquid biopsies into clinical practice. …

Vorheriger Artikel ASH 2023

Nächster Artikel Antibody–drug conjugates (ADC special)—part 2

Boos LA, Wicki A. The molecular tumorboard—a key element of precision oncology. memo. 2024; https://doi.org/10.1007/s12254-024-00977-7.CrossRef

Hasenleitner SOP, Heitzer E. Liquid profiling for patients with advanced cancer is ready for clinical integration. memo. 2024; https://doi.org/10.1007/s12254-024-00978-6.CrossRef

Titel: Molecular tumor board—editorial
verfasst von: Priv. Doz. Dr. Hossein Taghizadeh
Prof. Dr. Armin Gerger
Publikationsdatum: 01.09.2024
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-024-00989-3

Liquid biopsy in breast cancer

Open Access
short review

American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia

short review

Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023

Open Access
short review

Liquid profiling for patients with advanced cancer is ready for clinical integration

Open Access
short review

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Open Access
review

β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response

original report

Springer Medizin Österreich

Molecular tumor board—editorial

Auszug

Weitere Artikel der Ausgabe 3/2024

Liquid biopsy in breast cancer

American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia

Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023

Liquid profiling for patients with advanced cancer is ready for clinical integration

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response

Springer Medizin Österreich

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Liquid biopsy in breast cancer

American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia

Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023

Liquid profiling for patients with advanced cancer is ready for clinical integration

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response